MX2018014184A - Triple combinacion de antagonistas del receptor de 5-ht6 puro, inhibidores de acetilcolinesterasa y antagonista del receptor de nmda. - Google Patents
Triple combinacion de antagonistas del receptor de 5-ht6 puro, inhibidores de acetilcolinesterasa y antagonista del receptor de nmda.Info
- Publication number
- MX2018014184A MX2018014184A MX2018014184A MX2018014184A MX2018014184A MX 2018014184 A MX2018014184 A MX 2018014184A MX 2018014184 A MX2018014184 A MX 2018014184A MX 2018014184 A MX2018014184 A MX 2018014184A MX 2018014184 A MX2018014184 A MX 2018014184A
- Authority
- MX
- Mexico
- Prior art keywords
- receptor antagonist
- pure
- nmda
- acetylcholinesterase inhibitors
- triple combination
- Prior art date
Links
- 239000000544 cholinesterase inhibitor Substances 0.000 title abstract 3
- 229940044551 receptor antagonist Drugs 0.000 title abstract 3
- 239000002464 receptor antagonist Substances 0.000 title abstract 3
- 229940099433 NMDA receptor antagonist Drugs 0.000 title abstract 2
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 title abstract 2
- 108091005435 5-HT6 receptors Proteins 0.000 title 1
- 102100040368 5-hydroxytryptamine receptor 6 Human genes 0.000 abstract 2
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 abstract 2
- 101000964051 Homo sapiens 5-hydroxytryptamine receptor 6 Proteins 0.000 abstract 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 abstract 1
- 229940009098 aspartate Drugs 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000003751 serotonin 6 antagonist Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Indole Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invención se relaciona con una combinación de antagonista del receptor de 5-HT6 puro, inhibidor de acetilcolinesterasa y antagonista del receptor de NMDA. Asimismo, la presente invención se relaciona con antagonistas del receptor de 5-HT6 (5-HT6R) o sales farmacéuticamente aceptables de los mismos en combinación con o como un adjunto del inhibidor de acetilcolinesterasa y el antagonista del receptor de N-metil-D-aspartato (NMDA) y su uso en el tratamiento de trastornos cognitivos. La presente invención proporciona además la composición farmacéutica que contiene dicha combinación.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201641017204 | 2016-05-18 | ||
| PCT/IB2016/054672 WO2017199070A1 (en) | 2016-05-18 | 2016-08-03 | Triple combination of pure 5-ht6 receptor antagonists, acetylcholinesterase inhibitors and nmda receptor antagonist |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018014184A true MX2018014184A (es) | 2019-02-25 |
| MX384146B MX384146B (es) | 2025-03-14 |
Family
ID=56896730
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018014184A MX384146B (es) | 2016-05-18 | 2016-08-03 | Triple combinación de antagonistas del receptor de 5-ht6 puro, inhibidores de acetilcolinesterasa y antagonista del receptor de nmda. |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US11253514B2 (es) |
| EP (1) | EP3458039B1 (es) |
| JP (1) | JP6629464B2 (es) |
| KR (1) | KR102016120B1 (es) |
| CN (1) | CN109152751A (es) |
| AU (1) | AU2016407426B2 (es) |
| BR (1) | BR112018073410A2 (es) |
| CA (1) | CA3023836C (es) |
| CY (1) | CY1123644T1 (es) |
| DK (1) | DK3458039T3 (es) |
| EA (1) | EA038087B1 (es) |
| ES (1) | ES2815555T3 (es) |
| HK (1) | HK1258022A1 (es) |
| HR (1) | HRP20201412T1 (es) |
| HU (1) | HUE052077T2 (es) |
| IL (1) | IL262920B (es) |
| LT (1) | LT3458039T (es) |
| MA (1) | MA45002B1 (es) |
| MD (1) | MD3458039T2 (es) |
| MX (1) | MX384146B (es) |
| NZ (1) | NZ747797A (es) |
| PL (1) | PL3458039T3 (es) |
| PT (1) | PT3458039T (es) |
| RS (1) | RS60849B1 (es) |
| SG (1) | SG11201809726UA (es) |
| SI (1) | SI3458039T1 (es) |
| SM (1) | SMT202000521T1 (es) |
| WO (1) | WO2017199070A1 (es) |
| ZA (1) | ZA201807310B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110799189A (zh) * | 2017-07-03 | 2020-02-14 | 苏文生命科学有限公司 | 纯5-ht6受体拮抗剂的新用途 |
| JP7556031B2 (ja) * | 2019-12-02 | 2024-09-25 | スヴェン・ライフ・サイエンシーズ・リミテッド | 認知症患者の行動心理学的症状の治療 |
| MD4069231T2 (ro) * | 2019-12-02 | 2025-10-31 | Suven Life Sciences Ltd | Combinații de masupirdină cu donepezil sau memantină pentru tratarea simptomelor comportamentale și psihologice la pacienți cu demență |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003227516B2 (en) * | 2002-05-31 | 2008-03-20 | H. Lundbeck A/S | A combination of an NMDA-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease |
| CN101544592B (zh) | 2002-11-28 | 2013-08-21 | 苏文生命科学有限公司 | N-芳基磺酰-3-取代吲哚制备的替代方法 |
| US9018231B2 (en) * | 2010-01-05 | 2015-04-28 | Suven Life Sciences Limited | Sulfone compounds as 5-HT6 receptor ligands |
| WO2015083179A1 (en) * | 2013-12-02 | 2015-06-11 | Suven Life Sciences Limited | Process for large scale production of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1h-indole dimesylate monohydrate |
| CN105085436B (zh) * | 2014-04-19 | 2019-08-16 | 广东东阳光药业有限公司 | 磺酰胺类衍生物及其在药物上的应用 |
-
2016
- 2016-08-03 JP JP2018559327A patent/JP6629464B2/ja active Active
- 2016-08-03 MD MDE20190349T patent/MD3458039T2/ro unknown
- 2016-08-03 SG SG11201809726UA patent/SG11201809726UA/en unknown
- 2016-08-03 ES ES16763575T patent/ES2815555T3/es active Active
- 2016-08-03 RS RS20201045A patent/RS60849B1/sr unknown
- 2016-08-03 SM SM20200521T patent/SMT202000521T1/it unknown
- 2016-08-03 DK DK16763575.4T patent/DK3458039T3/da active
- 2016-08-03 EA EA201892528A patent/EA038087B1/ru unknown
- 2016-08-03 BR BR112018073410-1A patent/BR112018073410A2/pt not_active Application Discontinuation
- 2016-08-03 WO PCT/IB2016/054672 patent/WO2017199070A1/en not_active Ceased
- 2016-08-03 CN CN201680085589.7A patent/CN109152751A/zh active Pending
- 2016-08-03 MX MX2018014184A patent/MX384146B/es unknown
- 2016-08-03 HU HUE16763575A patent/HUE052077T2/hu unknown
- 2016-08-03 AU AU2016407426A patent/AU2016407426B2/en active Active
- 2016-08-03 PT PT167635754T patent/PT3458039T/pt unknown
- 2016-08-03 HR HRP20201412TT patent/HRP20201412T1/hr unknown
- 2016-08-03 CA CA3023836A patent/CA3023836C/en active Active
- 2016-08-03 NZ NZ747797A patent/NZ747797A/en unknown
- 2016-08-03 EP EP16763575.4A patent/EP3458039B1/en active Active
- 2016-08-03 US US16/097,752 patent/US11253514B2/en active Active
- 2016-08-03 KR KR1020187035888A patent/KR102016120B1/ko active Active
- 2016-08-03 MA MA45002A patent/MA45002B1/fr unknown
- 2016-08-03 LT LTEP16763575.4T patent/LT3458039T/lt unknown
- 2016-08-03 HK HK19100393.2A patent/HK1258022A1/zh unknown
- 2016-08-03 PL PL16763575T patent/PL3458039T3/pl unknown
- 2016-08-03 SI SI201630909T patent/SI3458039T1/sl unknown
-
2018
- 2018-10-31 ZA ZA2018/07310A patent/ZA201807310B/en unknown
- 2018-11-11 IL IL262920A patent/IL262920B/en active IP Right Grant
-
2020
- 2020-09-04 CY CY20201100834T patent/CY1123644T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2020000102A (es) | Compuestos útiles para inhibir a cdk7 | |
| MX2017004906A (es) | Dihidropirrolopiridinas inhibidoras del receptor huerfano-gamma. | |
| UY38001A (es) | Compuestos que inhiben las proteínas ras mutantes g12c | |
| MX2022012313A (es) | Oxisteroles y metodos de uso de los mismos. | |
| MX2022002976A (es) | Inhibidores selectivos de jak1. | |
| MX2020010737A (es) | Derivados de sulfamoilarilamida ciclados y su uso como medicamentos para el tratamiento de la hepatitis b. | |
| CL2019002900A1 (es) | Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton. | |
| MX382747B (es) | Derivados de pirimidina sustituidos con heterociclilo opcionalmente condensados útiles para el tratamiento de enfermedades inflamatorias, metabólicas oncológicas y autoinmunitarias. | |
| MX2016007410A (es) | Derivados del isocromeno como inhibidores de las fosfoinositido-3 cinasas. | |
| MX2018004664A (es) | Antagonistas de ep4. | |
| AR101414A1 (es) | Derivados de pirrolidinona como inhibidores de metap-2 | |
| CL2018003338A1 (es) | Formulaciones inyectables fisiológicamente balanceadas de fosnetupitant. | |
| ECSP16086247A (es) | (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina | |
| AR099766A1 (es) | Inhibidores de la quinasa asociada al adaptador 1, composiciones que los comprenden y métodos para utilizarlos | |
| MX2018014184A (es) | Triple combinacion de antagonistas del receptor de 5-ht6 puro, inhibidores de acetilcolinesterasa y antagonista del receptor de nmda. | |
| EA201892529A1 (ru) | Комбинация чистых антагонистов 5-htрецепторов с ингибиторами ацетилхолинэстеразы | |
| ECSP16086232A (es) | (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina | |
| MX2018013969A (es) | Combinacion de antagonistas del receptor 5-ht6 puro con un antagonista del receptor nmda. | |
| CO2021001925A2 (es) | Piridopirimidinas como inhibidores del receptor de histamina h4 | |
| CL2017002605A1 (es) | Derivados de indol | |
| CL2018002010A1 (es) | Derivados de indano y su uso en terapias. | |
| MX2019001698A (es) | Combinacion triple de agonistas inversos del receptor de histamina 3, inhibidores de la acetilcolinestearasa y antagonistas del receptor nmda. | |
| MX2019001696A (es) | Combinacion de agonistas inversos de receptor de histamina-3 con inhibidores de acetilcolinesterasa. | |
| UY35348A (es) | Derivados de carbazol inhibidores del bromodominio y composiciones que los contienen | |
| DOP2019000233A (es) | Dropropizina en combinacion con ambroxol en la forma farmaceutica de jarabe y tableta |